News
NUVL
123.96
0.00%
0.00
Nuvalent seeks Nasdaq delisting, plans to end SEC reporting after merger closes
PUBT · 07/15 13:04
*GSK Completes Acquisition of Nuvalent
Dow Jones · 07/15 12:39
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Barchart · 07/13 12:29
Weekly Report: what happened at NUVL last week (0706-0710)?
Weekly Report · 07/13 09:15
BUZZ-Biopharma dealmaking on way to record year, says HSBC
Reuters · 07/10 10:33
Biotech rally rests on fundamentals, M&A appetite, says ROTY's Faison
Seeking Alpha · 07/09 08:33
Nuvalent CEO James Richard Porter disposes of 30,000 common shares for $3.71 million
PUBT · 07/08 20:31
Nuvalent CFO Alexandra Balcom disposes of 11,430 common shares worth $1.41 million
PUBT · 07/06 20:31
Weekly Report: what happened at NUVL last week (0629-0703)?
Weekly Report · 07/06 09:15
Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)
TipRanks · 07/06 06:40
Nuvalent Chief Development Officer Darlene Noci disposes of 5,500 common shares worth $679,305.5
PUBT · 07/01 20:32
Weekly Report: what happened at NUVL last week (0622-0626)?
Weekly Report · 06/29 09:15
Record-setting healthcare M&A activity to extend through H2: PwC
Seeking Alpha · 06/25 17:59
Is GSK Quietly Becoming An Oncology Powerhouse
Seeking Alpha · 06/25 13:36
GSK Commences Tender Offer To Acquire Nuvalent At $124/Share
Benzinga · 06/24 15:16
GSK announces commencement of tender offer to acquire Nuvalent
TipRanks · 06/24 14:00
*GSK Agreed to Acquire Nuvalent on June 9
Dow Jones · 06/24 13:57
BRIEF-GSK Announces Tender Offer To Acquire Nuvalent
Reuters · 06/24 13:55
*GSK: Harmony Row Acquisition Has Started a Tender Offer
Dow Jones · 06/24 13:54
*GSK Announces Tender Offer to Buy Nuvalent
Dow Jones · 06/24 13:53
More
Webull provides a variety of real-time NUVL stock news. You can receive the latest news about Nuvalent, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.